Special Feature

User Panel

My Panel

My Panel

Bookmark Science Articles

Recent News
Bookmark / Share This Science Site

Quality of clinical and economic evidence in dossier formulary submissions.

Quality of clinical and economic evidence in dossier formulary submissions. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

  • Abstract Text of This Paper
  • Journal Published
  • MeSH Keywords of This Abstract
  • Chemicals and Substances Used in this Paper
  • Grants and Granting Agency of this Research
  • Database Accession Numbers Used in this Paper
  • Related Papers
  • Related Research Tags
  • Rate this Research Paper
  • Quality of clinical and economic evidence in dossier formulary submissions. Abstract Text:

    fernando colmeneroFernando Colmenero,sean d sullivanSean D Sullivan,jennifer a palmerJennifer A Palmer,carmen a brauerCarmen A Brauer,kathleen bungayKathleen Bungay,john watkinsJohn Watkins,peter j neumannPeter J Neumann,

    OBJECTIVE: To investigate the quality and completeness of clinical and economic data in dossiers submitted by drug companies to a health plan using Academy of Managed Care Pharmacy guidelines (the Format) for formulary submissions. STUDY DESIGN: We reviewed the quality of economic analyses in dossiers submitted to Premera Blue Cross Health Plan (Mountlake Terrace, Washington; enrollment 1.6 million) between January 2002 and September 2005. For dossiers submitted in 2003, we examined the clinical studies included. METHODS: Dossiers were audited with a data collection form to judge the types of clinical studies used to support labeled and off-label indications, and the quality and transparency of economic analyses. We compared economic analyses for high-cost (30-day treatment cost > $1000) versus low-cost products, and for "innovative" versus "me-too" drugs. RESULTS: Evidence to support off-label indications often was included in 2003 dossiers, but the information was less extensive and of poorer quality than data for labeled indications. Of 115 dossiers submitted between 2002 and 2005, 53 (46%) included economic analyses. The economic analyses had low levels of compliance with standards: only 43% performed sensitivity analysis; 38% stated the study perspective; 37% discussed relevant treatment alternatives; 20% stated assumptions clearly; and 18% mentioned caveats to conclusions. Economic analyses of high-cost products and innovative products had higher compliance with recommended practices. CONCLUSIONS: Drug companies are submitting dossiers of evidence to formulary committees. Dossiers often included clinical data to support off-label indications, but concerns persist about their quality. About half of dossiers included economic analyses, but these analyses had relatively low levels of compliance with recommended practices.

    Quality of clinical and economic evidence in dossier formulary submissions. Publishing Authors By Initials

    f colmeneroF Colmenero,sd sullivanSD Sullivan,ja palmerJA Palmer,ca brauerCA Brauer,k bungayK Bungay,j watkinsJ Watkins,pj neumannPJ Neumann,

    For similar geographic locations: americas: north america: united states research abstracts see: geographic locations: americas: north america: united states research

    PUBMED ID PMID:

    MEDLINE DATE:

    Quality of clinical and economic evidence in dossier formulary submissions. Journal Published:

    PUBLICATION TYPE: Research Support, U.S. Gov't,

    Journal: The American journal of managed care

    VOLUME: 13

    Page Numbers: 401-7

    Journal Abbreviation:

    ISSN: 1936-2692

    DAY: 3

    MONTH: Jul

    YEAR: 2007

    Quality of clinical and economic evidence in dossier formulary submissions. Information

    Number of References:

    LANGUAGE: eng

    NlmUniqueID: 9613960

    Quality of clinical and economic evidence in dossier formulary submissions. Keywords Mesh Terms:

    KEYWORDS: United States

    MESH TERMS: standards

    Chemical & Substance for Abstract: Quality of clinical and economic evidence in dossier formulary submissions. Information

    Substance Name:

    Registry Number:

    Grant and Affiliation Information for Quality of clinical and economic evidence in dossier formulary submissions.

    AFFILIATION: Harvard School of Public Health, Boston, MA, USA.

    Country: United States

    United States Research PublicationUnited States Research Publication

    AGENCY: United States PHS

    GRANT: HHSP233200400483A

    ACRONYM:

    MEDLINETA: Am J Manag Care

    REFSOURCE:

    DATABASENAME:

    ACCESSION NUMBER:

    Number Hits: 0

    Quality of clinical and economic evidence in dossier formulary submissions Related Publications

     

    Molecular Station USER Menu

    Welcome to Molecular Station!

    You have to register before you can post on our forums or use our advanced features. Register Now! Its Free and Fast!

    Already registered? Login now below.

    User Name:

    Password:

    Already registered and Forgot your password? Click below to recover it.

    Recover Lost Password

    Join now - it's fast and free!

    Molecular Station is THE largest network of researchers, scientists and science lovers anywhere!

    Research Terms of Usage and Disclaimer
    Home
    Features

    Protocols

    DNA Forum

    Science Forum

    DNA Forum
    Biology Forum

    Science News


    [CaRP] XML error: Invalid document end at line 2

    For more click here:Science News